PY-159 is under clinical development by Pionyr Immunotherapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PY-159’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PY-159 overview

PY-159 is under development for the treatment of solid tumors including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+), HER-2 negative Breast Cancer (HER-2-)], head and neck squamous cell carcinoma, thyroid cancer, salivary gland cancer, pancreatic ductal adenocarcinoma (PDAC), fallopian tube cancer, peritoneal cancer, colorectal cancer, lung adenocarcinoma, lung squamous cell carcinoma, gastric and esophagogastric junction adenocarcinomas, pancreatic adenocarcinoma, gynecological cancers including ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, uterine cancer and vulvar cancer. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody developed based on myeloid tuning technology. It acts by targeting TREM1.

Pionyr Immunotherapeutics overview

Pionyr Immunotherapeutics (Pionyr) discovers and develops cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is investigating pipeline programs PY314 a cell surface receptor, TREM2 for targeted depletion of tumor-associated macrophages (TAMS) and PY159, TREM1 for targeted reprogramming of immunosuppressive myeloid cells. It focuses to develop Myeloid Tuning, a technology that is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment. Pionyr works in collaboration with ProBioGen AG, Celonic AG and Gilead Sciences Inc. Pionyr is headquartered in San Francisco, California, the US.

For a complete picture of PY-159’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.